June 30, 2025

Breakthrough Device Approvals Outpacing Data

Many FDA-authorized breakthrough therapeutic devices may lack robust clinical testing.

Conexiant

June 30, 2025

Can Typos Change a Diagnosis?

Large language models used in clinical decision-making may offer different treatment recommendations depending on how a patient writes their message—even when the medical facts remain unchanged.

Conexiant

June 27, 2025

Weight Loss Drugs, Heavier Implications

New guidance positions GLP-1 and GLP-1/GIP therapies as frontline options for long-term weight management—with profound implications for cardiovascular outcomes, access equity, and chronic disease care.

Conexiant

June 24, 2025

Cannabis Use Linked to Higher Heart Risks

A new systematic review and meta-analysis found that cannabis use is associated with an increased risk of major adverse cardiovascular events—including acute coronary syndrome, stroke, and cardiovascular death—based on data from more than 432 million individuals in 24 observational studies.

Conexiant

June 23, 2025

Sitting-Rising Test Predicts Long-Term Mortality Risk

A 12-year study of over 4,000 adults found that poor performance on a basic sitting and rising test was strongly linked to increased risk of death from natural and cardiovascular causes.

Conexiant

June 20, 2025

Gut Bacteria Predict Chemotherapy-Related Heart Damage

Specific gut bacteria correlate with biomarkers indicating increased risk of cardiotoxicity in breast cancer patients before chemotherapy treatment.

Conexiant

June 19, 2025

Heavy Drinking Consistently Linked To Heart Risks

New research finds that heavy alcohol consumption consistently raises cardiovascular risks, while evidence for protective effects of light drinking remains inconclusive.

Conexiant

June 18, 2025

SGLT2 Inhibitor Empagliflozin Preserves Kidney Function After Heart Attack

A secondary analysis of the EMPACT-MI trial, published in Nature Cardiovascular Research, shows that the sodium-glucose cotransporter-2 (SGLT2) inhibitor empagliflozin stabilizes kidney function and reduces heart failure hospitalizations in patients who have recently experienced a heart attack.

Conexiant

June 16, 2025

Cytisinicline Shows Efficacy In Smoking Cessation Trial 

A phase 3 randomized clinical trial found that cytisinicline, a partial agonist at α4β2 nicotinic acetylcholine receptors, improved smoking cessation rates compared with placebo, with higher abstinence rates and reduced craving over 24 weeks.

Conexiant